Answers are grounded in this paper and cite their sources.
Current guidelines recommend quantitative neuromuscular block monitoring during neuromuscular blocking agent administration. Monitors using surface electromyography (EMG) determine compound motor action potential (cMAP) amplitude or area under the curve (AUC). Rigorous evaluation of the interchangeability of these methods is lacking but necessary for clinical and research assurance that EMG interpretations of the depth of neuromuscular block are not affected by the methodology.
No takes yet. Share an insight, caveat, or question.
Epstein et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: